Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation.

BACKGROUND AIMS. Previously, cytotoxic T lymphocyte antigen 4 (CTLA4) immunoglobulin (Ig) has been shown to allow sustained engraftment in dog leukocyte antigen (DLA)-identical hematopoietic cell transplant (HCT) after non-myeloablative conditioning with 100 cGy total body irradiation (TBI). In the current study, we investigated the efficacy of pre-transplant CTLA4-Ig in promoting engraftment across a DLA-mismatched barrier after non-myeloablative conditioning. METHODS. Eight dogs were treated with CTLA4-Ig and donor peripheral blood mononuclear cells (PBMC) prior to receiving 200 cGy TBI followed by transplantation of granulocyte-colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells from DLA haplo-identical littermates with post-grafting immunosuppression. A control group of six dogs was conditioned with 200 cGy only and transplanted with grafts from DLA haplo-identical littermates followed by post-grafting immunosuppression. RESULTS. In vitro and in vivo donor-specific hyporesponsiveness was demonstrated on day 0 before TBI in eight dogs that received CTLA4-Ig combined with donor PBMC infusions. Four of five dogs treated with increased doses of CTLA4-Ig achieved initial engraftment but eventually rejected, with a duration of mixed chimerism ranging from 12 to 22 weeks. CTLA4-Ig did not show any effect on host natural killer (NK) cell function in vitro or in vivo. No graft-versus-host disease (GvHD) was observed in dogs receiving CTLA4-Ig treatment. CONCLUSIONS. Non-myeloablative conditioning with 200 cGy TBI and CTLA4-Ig combined with donor PBMC infusion was able to overcome the T-cell barrier to achieve initial engraftment without GvHD in dogs receiving DLA haplo-identical grafts. However, rejection eventually occurred; we hypothesize because of the inability of CTLA4-Ig to abate natural killer cell function.

[1]  R. Wiseman,et al.  An MHC‐Defined Primate Model Reveals Significant Rejection of Bone Marrow After Mixed Chimerism Induction Despite Full MHC Matching , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  R. Storb,et al.  Plerixafor-moblized stem cells alone are capable of inducing early engraftment across the MHC-haploidentical canine barrier. , 2010, Blood.

[3]  L. Lundquist.  Abatacept: A novel therapy approved for the treatment of patients with rheumatoid arthritis , 2007, Advances in therapy.

[4]  J. Dipersio,et al.  AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. , 2007, Future oncology.

[5]  M. Cottler-Fox,et al.  Mobilization and collection of autologous hematopoietic progenitor/stem cells. , 2007, Clinical advances in hematology & oncology : H&O.

[6]  R. Storb,et al.  Dog Leukocyte Antigen-Haploidentical Stem Cell Allografts After Anti-CD44 Therapy and Nonmyeloablative Conditioning in a Preclinical Canine Model , 2006, Transplantation.

[7]  M. Sayegh,et al.  T‐cell costimulatory pathways in allograft rejection and tolerance , 2003, Immunological reviews.

[8]  R. Foster,et al.  Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade , 2003, Transplantation.

[9]  K. Okumura,et al.  Role of the CTLA4 pathway in hyporesponsiveness induced by intratracheal delivery of alloantigen1 , 2003, Transplantation.

[10]  R. Storb,et al.  Percutaneous Central Dual-Lumen Catheter for Apheresis in the Canine , 2002, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[11]  E. Reinherz,et al.  Critical role of NK but not NKT cells in acute rejection of parental bone marrow cells in F1 hybrid mice , 2001, European journal of immunology.

[12]  R. Storb,et al.  G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. , 1999, Blood.

[14]  R. Storb,et al.  The use of an anti-TCRalphabeta monoclonal antibody to control host-versus-graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation. , 1999, Transplantation.

[15]  A. Sharpe,et al.  The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. , 1999, Journal of immunology.

[16]  A. Sharpe,et al.  The role of B7 co‐stimulation in activation and differentiation ofCD4+and CD8+T cells , 1998, Immunological reviews.

[17]  R. Storb,et al.  DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. , 1998, Tissue antigens.

[18]  R. Storb,et al.  Epitope Specificity of CD44 for Monoclonal Antibody–Dependent Facilitation of Marrow Engraftment in a Canine Model , 1998 .

[19]  G. Szot,et al.  Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. , 1997, Journal of immunology.

[20]  T. Mak,et al.  Acute graft-versus-host disease without costimulation via CD28. , 1997, Transplantation.

[21]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.

[22]  C. Fathman,et al.  Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig. , 1996, Transplantation.

[23]  P. Linsley,et al.  CTLA4Ig inhibits alloantibody responses to repeated blood transfusions. , 1996, Blood.

[24]  R. Storb,et al.  Molecular analysis of DLA-DRBB1 polymorphism. , 1996, Tissue antigens.

[25]  E. Ostrander,et al.  Histocompatibility testing of dog families with highly polymorphic microsatellite markers. , 1996, Transplantation.

[26]  H. Deeg,et al.  Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors , 1996 .

[27]  J. S. Lee,et al.  Pharmacokinetics and pharmacodynamics of CTLA4lg (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses. , 1996, Journal of pharmaceutical sciences.

[28]  N. Srinivas,et al.  Pharmacokinetics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following intravenous and subcutaneous administration to mice. , 1995, Journal of pharmaceutical sciences.

[29]  P. Linsley,et al.  CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. , 1995, Journal of immunology.

[30]  B. Sandmaier,et al.  Characterization of an anti-CD44 single-chain FV antibody that stimulates natural killer cell activity and induces TNF alpha release. , 1995, Immunological investigations.

[31]  B. Sandmaier,et al.  Mechanisms of enhancement of natural killer activity by an antibody to CD44: increase in conjugate formation and release of tumor necrosis factor alpha. , 1995, Cellular immunology.

[32]  P. Linsley,et al.  CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. , 1994, Transplantation.

[33]  E. Bryant,et al.  USE OF (CA)n POLYMORPHISMS TO DETERMINE THE ORIGIN OF BLOOD CELLS AFTER ALLOGENEIC CANINE MARROW GRAFTING , 1994, Transplantation.

[34]  B. Sandmaier,et al.  'Resistance' to unrelated, DLA-nonidentical canine marrow grafts is unrestricted by the major histocompatibility complex. , 1994, Experimental hematology.

[35]  P. Linsley,et al.  Transplantation tolerance induced by CTLA4-Ig. , 1994, Transplantation.

[36]  C. Jacobsen,et al.  Reactivities of 20 anti-human monoclonal antibodies with leucocytes from ten different animal species. , 1993, Veterinary immunology and immunopathology.

[37]  P. Linsley,et al.  Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion , 1993, The Journal of experimental medicine.

[38]  H. Deeg,et al.  Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. , 1993, International journal of radiation oncology, biology, physics.

[39]  B. Sandmaier,et al.  Enhancement of natural killer activity by an antibody to CD44. , 1993, Journal of immunology.

[40]  P. Linsley,et al.  T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Linsley,et al.  Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. , 1992, Science.

[42]  D. Danilenko,et al.  Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lymphocyte subsets and high-density expression of CD4 by canine neutrophils. , 1992, Tissue antigens.

[43]  J. Allison,et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.

[44]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.

[45]  I. Bernstein,et al.  Biochemical characterization of a unique canine myeloid antigen. , 1991, Leukemia.

[46]  R. Storb,et al.  An antibody that facilitates hematopoietic engraftment recognizes CD44. , 1990, Blood.

[47]  R. Storb,et al.  Canine models of bone marrow transplantation. , 1990, Laboratory animal science.

[48]  P. Lacy,et al.  EFFECT OF LOW‐TEMPERATURE CULTURE ON THE SURVIVAL OF INTRATESTICULAR RAT ISLET ALLOGRAFTS1 , 1988 .

[49]  H. Deeg,et al.  FAILURE OF ANTITHYMOCYTE SERUM POSTGRAFTING TO OVERCOME “RESISTANCE” TO DLANONIDENTICAL CANINE MARROW GRAFTS1 , 1988, Transplantation.

[50]  H. Deeg,et al.  Characterization of host cells involved in resistance to marrow grafts in dogs transplanted from unrelated DLA-nonidentical donors. , 1986, Blood.

[51]  H. Deeg,et al.  Morphologic and phenotypic analysis of canine natural killer cells: evidence for T-cell lineage. , 1985, Cellular immunology.

[52]  I. Bernstein,et al.  Influence of antibody isotype on passive serotherapy of lymphoma. , 1985, Journal of immunology.

[53]  H. Deeg,et al.  The canine major histocompatibility complex. Population study of DLA-D alleles using a panel of homozygous typing cells. , 2008, Tissue antigens.

[54]  R. Storb,et al.  HEMOPOIETIC GRAFTS BETWEEN DLA‐IDENTICAL CANINE LITTERMATES FOLLOWING DIMETHYL MYLERAN: EVIDENCE FOR RESISTANCE TO GRAFTS NOT ASSOCIATED WITH DLA AND ABROGATED BY ANTITHYMOCYTE SERUM , 1977, Transplantation.